PMID: 15218813Jun 29, 2004Paper

The PROMiSe trial: baseline data review and progress report

Multiple Sclerosis : Clinical and Laboratory Research
J S Wolinsky, PROMiSe Trial Study Group

Abstract

The PROMiSe trial is a multinational, multicentre, double-blind, placebo-controlled trial evaluating the effects of glatiramer acetate treatment over 3 years in patients with primary progressive multiple sclerosis (PPMS). A total of 943 patients were enrolled, and all those remaining on-study had completed at least 24 months as of October 2002. Baseline clinical and MRI characteristics and select correlations are reported here. A total of 3.9% of patients exhibited confirmed relapse over 1904 patient-years of exposure, indicating success of efforts to exclude relapsing MS types. Of the 26.3% of patients who have prematurely withdrawn from the study, only 36% discontinued after meeting the study primary endpoint of disease progression. The progression rate in patients in the low Expanded Disability Status Scale (EDSS) stratum (3.0-5.0) observed thus far is markedly lower than the 50% annual progression rate estimate used for determining size and statistical power of the trial; progression was observed in 16.1% of patients with 12 months of study exposure. These early findings raise some concern about the ability of the trial to demonstrate a significant treatment effect, and suggest that the short-term natural history of PPMS ma...Continue Reading

Citations

May 17, 2005·Physical Medicine and Rehabilitation Clinics of North America·James Bowen
Oct 10, 2012·The Pharmacogenomics Journal·V Foti CuzzolaS Marino
Sep 30, 2010·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Rachel A Farrell, Gavin Giovannoni
Jun 24, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·M BieniekD H Miller
Apr 1, 2007·Neuropsychiatric Disease and Treatment·Alex TselisRobert P Lisak
Jun 21, 2007·Journal of Neurology·M DebouverieH Vespignani
Nov 16, 2007·Journal of Neurology·Christoph KleinschnitzHeinz Wiendl
May 12, 2009·Journal of the Neurological Sciences·Jerry S WolinskyUNKNOWN PROMiSe Trial Study Group
Dec 11, 2008·Neuroimaging Clinics of North America·Anthony Traboulsee, David K B Li
Sep 22, 2007·Lancet Neurology·David H Miller, Siobhan M Leary
Dec 30, 2014·Journal of Pineal Research·Antonio López-GonzálezAntonio Carrillo-Vico
Sep 12, 2014·Acta Neurologica Scandinavica·M MagyariP S Sørensen
Nov 3, 2005·Expert Opinion on Emerging Drugs·Rachel FarrellGavin Giovannoni
Jan 1, 2014·Multiple Sclerosis and Related Disorders·K S PandeyF D Lublin
Jun 28, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Helen TremlettUNKNOWN BC MS Clinic Neurologists
Sep 2, 2008·Expert Review of Neurotherapeutics·Albert Lo
Sep 1, 2006·Expert Review of Clinical Immunology·Niels HellingsPiet Stinissen
Aug 6, 2010·Multiple Sclerosis : Clinical and Laboratory Research·Sara LlufriuAlbert Saiz
Mar 6, 2010·Multiple Sclerosis : Clinical and Laboratory Research·Z KhaleeliA J Thompson
Dec 10, 2009·Multiple Sclerosis : Clinical and Laboratory Research·X MontalbanA J Thompson
Feb 1, 2007·Multiple Sclerosis : Clinical and Laboratory Research·H ButzkuevenJ P Malkowski
Jan 3, 2019·Journal of Biopharmaceutical Statistics·Qing Shu LuSiu-Keung Tse
Jul 20, 2005·Expert Review of Neurotherapeutics·Domenico M MezzapesaMassimo Filippi
Dec 2, 2005·International Reviews of Immunology·Paulo FontouraLawrence Steinman
May 14, 2010·The Cochrane Database of Systematic Reviews·Loredana La MantiaRoberta Lovati
Oct 30, 2013·Neurologia i neurochirurgia polska·W BrolaD Ryglewicz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.